无码AV天堂一区二区三区_免费观看又色又爽又黄的崩锅_夜夜春夜夜爽_亚洲aⅴ无码成人网站国产_日本老熟妇乱子伦视频_男女啪啪高潮激烈免费版_国产狂喷潮在线观看_国产成人一区二区三区免费视频_性色av无码专区一ⅴa亚洲_

SMET12 is a fully human bispecific antibody targeting EGFR on tumor cells and CD3 on T cells. Developed based on CentryMed's proprietary antibody screening library and bispecific antibody platform, it is the world's first intravenous EGFR×CD3 bispecific antibody and the first in China to receive clinical trial approval from the NMPA. SMET12 recruits and activates T cells to release cytokines, directly killing tumor cells with a low risk of cytokine release syndrome (CRS).

DNV3 is a LAG-3 antibody developed from CentryMed's proprietary high-capacity IgM antibody library. Representing one of the most promising immune checkpoint inhibitors beyond PD-1/PD-L1, DNV3 was initially developed for autoimmune diseases. Preclinical and clinical data indicate its strong potential to reverse resistance to PD-1/PD-L1 inhibitors. DNV3 binds to LAG-3 on activated T cells, directly activating the LAG-3 pathway. This initiates LAG-3 signaling, inhibiting T cell activity, eliminating inflammatory responses, and ultimately normalizing inflammation and maintaining immune homeostasis.

CMDE005 is a recombinant human anti-EGFR×CD3 enzyme-controlled bispecific antibody developed using CentryMed's proprietary pro-BiTE platform. This drug candidate offers advantages including high expression yield during production, high stability, and a long half-life. It is intended for treating various EGFR-positive advanced solid tumors. CMDE005 received clinical trial approval from China's NMPA in September 2024 and IND clearance from the US FDA in April 2025. The drug is currently in Phase I clinical trials, with patient enrollment ongoing in the fifth dose cohort, placing its clinical progress among the global leaders for this class of therapeutics.